Michael Dunn, PhD, MBA

Experience

• 

  Roche

  Mar 2010 - Apr 2013

  -Responsible for planning, technical conduct, and reporting of general toxicology, reproductive toxicology, teratology, and/or safety pharmacology studies in compliance with GLP regulations.-Responsible for the generation of regulatory documents (IB, expert opinion white papers) in support of development compounds.-Responsible for development and maintenance of toxicology-related animal research protocols; voting member of Roche IACUC and Dept. Non-Clinical Safety direct contact to IACUC.-Leader of the cardiovascular biomarker working group; responsible for managing scientific investigation into the biological significance of cardiac troponin I and other cardiovascular biofluid biomarkers.-Serve as the corporate representative for PSTC (co-chair Cardiac Hypertrophy Working Group) and ILSI/HESI consortium groups whose goals were aligned with the qualification of cardiovascular biofluid biomarkers and cardiovascular imaging tools for use in the non-clinical safety evaluation of compounds in development. -Co-leader of department-wide initiative to improve engagement of co-workers though workplace process improvement, management/senior leadership training and enhanced communication at all levels. Show less

  • Scientist

    Jul 2011 - Apr 2013

  • Post Doc

    Mar 2010 - Jul 2011
• 

  Regeneron

  Jun 2013 - Dec 2022

  • Associate Director and Chief of Staff, Clinical Sciences General Medicine

    Jul 2021 - Dec 2022

  • Associate Director, Cardiovascular & Renal Research

    Jan 2021 - Jul 2021

  • Senior Staff Scientist, Cardiovascular Research

    Jan 2018 - Jan 2021

  • Staff Scientist, Cardiovascular Research

    Jun 2013 - Jan 2018
• 

  Regeneron

  Oct 2023 - now

  • Director, Regulatory Affairs

    Jul 2024 - now

  • Director and Chief of Staff, Global Clinical Development, Internal Medicine

    Jan 2023 - Jul 2024

  • Interim Global Program Head - Allergy

    Oct 2023 - May 2024